Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||EX8680 / 1||- / -|
Administered by: Other Purchased by: ??
Symptoms: Facial paralysis, Eyelid function disorder
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? Yes
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Diagnostic Lab Data:
CDC 'Split Type': DEPFIZER INC2021639321
Write-up: This is a spontaneous report from a contactable consumer (patient''s wife), based on information received by Pfizer from BioNTech (control number: 60390), licensed party for BNT162B2 (Comirnaty). A 64-year-old male patient received the first dose of BNT162B2 (Comirnaty, solution for injection, lot# EX8680), at the age of 64, via an unknown route, on May 11, 2021, single dose, for COVID-19 immunisation. No medical history or concomitant medications provided. Since Jun 1, 2021, patient has unilateral facial paralysis (medically significant). He can''t shut his eye completely, eyelid problems (non-serious). The patient visited the doctor. He was given cortisone tablets and eye ointment. The patient has not recovered from the events.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166